Pierre Fabre Enhances I&D Portfolio with Acquisition of PFL-721 and PFL-241

Pierre Fabre Laboratories, based in Castres, France, has announced the acquisition of the global rights for PFL-721 and PFL-241, previously known as STX-721 and STX-241. These are specific mutant EGFR inhibitors being developed for the treatment of non-small cell lung cancer, NSCLC, addressing emerging and unmet medical needs. This acquisition agreement expands Pierre Fabre's previous partnership with Scorpion Therapeutics and includes taking charge of the clinical development of these drugs. PFL-721 targets exon 20 mutants of EGFR and HER2 and is expected to undergo a clinical trial to optimize its dosage. PFL-241, a fourth-generation EGFR mutant-specific inhibitor with brain penetration capabilities, aims to address C797S resistance mutations in NSCLC patients. This acquisition allows Pierre Fabre to possess global rights to all assets in its R&D portfolio, including exarafenib and PFL-002. The company's R&D team is committed to advancing these programs to offer novel and differentiated precision medicines tailored to patients with significant unmet needs. Pierre Fabre Laboratories is renowned for its dermocosmetic brands and is a leading pharmaceutical entity in Europe, involved in oncology, dermatology, rare diseases, primary care, and family health.